Ovarian Suppression in Patients with Hormone-Receptor–Positive Breast Cancer

Updated guidelines suggest that higher-risk patients should receive ovarian suppression in addition to standard adjuvant therapy, but lower-risk patients should not.

Sponsoring Organization: American Society of Clinical Oncology (ASCO)

Target Audience: Medical, surgical, and radiation oncologists; oncology nurses and physician assistants; obstetrician-gynecologists; general practitioners; and premenopausal women with stage I–III, hormone-receptor–positive breast cancer

Background

In 2011, ASCO endorsed a guideline from Cancer Care Ontario that recommended against adding ovarian suppression to tamoxifen or chemotherapy or both as adjuvant treatment for premenopausal women with early-stage invasive breast cancer (J Clin Oncol 2011; 29:3939). In 2014, ASCO published a focused update based on subsequent data regarding the duration of treatment, primarily with adjuvant tamoxifen (J Clin Oncol 2014; 32:2255). No…

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)